Page 48 - 2019_11 Resto del Mondo-web

M. Fürstenau et al.
nib in chronic lymphocytic leukemia. J Clin
Oncol. 2017;35(13):1437-1443.
48. Byrd JC, Hillmen P, O'Brien S, et al. Long-
term follow-up of the RESONATETM phase 3 trial of ibrutinib versus ofatumumab. Blood. 2019;133(19):2031-2042.
49. Chen Q, Jain N, Ayer T, et al. Economic Burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166- 174.
50. Spina V, Forestieri G, Zucchetto A, et al. Mechanisms of adaptation to ibrutinib in high risk chronic lymphocytic leukemia. Blood. 2018;132(Suppl 1):585.
51. EMA. (European Medicines Agency). Appendix 4 to the guideline on the evalua- tion of anticancer medicinal products in man - condition specific guidance. https://wwwemaeuropaeu/en/appendix-4- guideline-evaluation-anticancer-medicinal- products-man-condition-specific-guidance . 2016.
52. Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-988.
53. Goede V, Fischer K, Busch R, t al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting condi- tions. N Engl J Med. 2014;370(12):1101- 1110.
54. Kovacs G, Robrecht S, Fink AM, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehen- sive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016;34(31):3758-3765.
55. Langerak AW, Ritgen M, Goede V, et al. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood. 2019;133(5):494-497.
56. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, ben- damustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211.
57. Fraser G, Cramer P, Demirkan F, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and ritux- imab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2019;33(4):969-980.
58. Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lympho- cytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-con- trolled trial. Lancet Oncol. 2017;18(3):297- 311.
59. Davids MS, Brander DM, Kim HT, et al. Ibrutinib plus fludarabine, cyclophos- phamide, and rituximab as initial treatment for younger patients with chronic lympho- cytic leukaemia: a single-arm, multicentre,
phase 2 trial. Lancet Haematol. 2019;
6(8):e419-e28.
60. Jain N, Thompson PA, Burger JA, et al.
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for firstline treat- ment of patients with CLL with mutated IGHV and without TP53 aberrations. Blood. 2018;132(Suppl 1):695.
61. Michallet A-S, Dilhuydy M-S, Subtil F, et al. High rate of complete response (CR) with undetectable bone marrow minimal residual disease (MRD) after chemo-sparing and MRD-driven strategy for untreated fit CLL patients: final results of the Icll 07 FILO trial. Blood. 2018;132(Suppl 1):1858.
62. Davids MS. A Phase Ib/II study of duvelisib in combination with FCR (dFCR) for front- line therapy of younger CLL patients. EHA Annual Meeting; oral presentation. 2018.
63. Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib versus ibruti- nib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019; 133(10):1011-1019.
64. Woyach JA, Awan FT, Jianfar M, et al. Acalabrutinib with obinutuzumab in relapsed/refractory and treatment-naive patients with chronic lymphocytic leukemia: the phase 1b/2 ACE-CL-003 study. Blood. 2017;130(Suppl 1):432.
65. Cramer P, von Tresckow J, Robrecht S, et al. Bendamustine followed by ofatumumab and ibrutinib in patients with chronic lym- phocytic leukemia (CLL): CLL2-BIO trial of the German CLL Study Group (GCLLSG). Blood. 2017;130(Suppl 1):494.
66. von Tresckow J, Cramer P, Bahlo J, et al. CLL2-BIG: sequential treatment with ben- damustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019;33(5):1161-1172.
67. Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215- 1228.
68. Cramer P, von Tresckow J, Bahlo J, et al. Durable remissions after discontinuation of combined targeted treatment in patients with chronic lymphocytic leukemia (CLL) harbouring a high-risk genetic lesion (del(17p)/TP53 mutation). Blood. 2018;132 (Suppl 1):694.
69. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. The N Engl J Med. 2019;380(23):2225-2236.
70. Flinn IW, Gribben JG, Dyer MJS, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019 Mar 12. [Epub ahead of print]
71. Hillmen P, Rawstron A, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refrac- tory CLL: results of the Bloodwise TAP Clarity Study. Blood. 2018;132(Suppl 1):182.
72. Jain N, Keating M, Thompson P, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019; 380(22):2095-2103.
73. Rogers KA, Huang Y, Ruppert AS, et al. Phase 2 study of combination obinutuzum- ab, ibrutinib, and venetoclax in treatment-
naive and relapsed/refractory chronic lym- phocytic leukemia. Blood. 2018;132(Suppl 1):693.
74. Davids MS, Kim HT, Nicotra A, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lym- phoma: a multicentre phase 1-1b study. Lancet Haematol. 2019;6(1):e38-e47.
75. Nastoupil LJ, Lunning MA, Vose JM, et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non- Hodgkin lymphoma: a phase 1 dose escala- tion and expansion trial. Lancet Haematol. 2019;6(2):e100-e109.
76. Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129(26):3419-3427.
77. Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non- Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematol. 2019;6(2):e67-e78.
78. Mato AR, Thompson M, Allan JN, et al. Real- world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511-1517.
79. Chen Q, Jain N, Ayer T, et al. Economic bur- den of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166-174.
80. Kadri S, Lee J, Fitzpatrick C, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017;1 (12):715-727.
81. Landau DA, Sun C, Rosebrock D, et al. The evolutionary landscape of chronic lympho- cytic leukemia treated with ibrutinib target- ed therapy. Nat Commun. 2017;8(1):2185.
82. Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129 (18):2581-2584.
83. Ghez D, Calleja A, Protin C, et al. Early- onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955-1959.
84. Bercusson A, Colley T, Shah A, Warris A, Armstrong-James D. Ibrutinib blocks Btk- dependent NF-kB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132 (18):1985-1988.
85. Waldron M, Winter A, Hill BT. Pharmacokinetic and pharmacodynamic considerations in the treatment of chronic lymphocytic leukemia: ibrutinib, idelalisib, and venetoclax. Clin Pharmacokinet. 2017;56(11):1255-1266.
86. Baliakas P, Jeromin S, Iskas M, et al. Cytogenetic complexity in chronic lympho- cytic leukemia: definitions, associations and clinical impact. Blood. 2019;133(11):1205- 1216.
87. Visentin A, Deodato M, Mauro FR, et al. A Scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia and its validation in a cohort of ibrutinib- treated patients. Blood. 2018;132 (Suppl 1):3118.
2154
haematologica | 2019; 104(11)